Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Gross Margin (2017 - 2020)

Historic Gross Margin for Ironwood Pharmaceuticals (IRWD) over the last 7 years, with Q4 2020 value amounting to 99.23%.

  • Ironwood Pharmaceuticals' Gross Margin rose 79500.0% to 99.23% in Q4 2020 from the same period last year, while for Dec 2020 it was 99.19%, marking a year-over-year increase of 64400.0%. This contributed to the annual value of 99.19% for FY2020, which is 47700.0% up from last year.
  • According to the latest figures from Q4 2020, Ironwood Pharmaceuticals' Gross Margin is 99.23%, which was up 79500.0% from 100.0% recorded in Q3 2020.
  • Over the past 5 years, Ironwood Pharmaceuticals' Gross Margin peaked at 100.0% during Q2 2020, and registered a low of 83.58% during Q4 2018.
  • Over the past 4 years, Ironwood Pharmaceuticals' median Gross Margin value was 95.61% (recorded in 2018), while the average stood at 94.85%.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -68900bps in 2018, then skyrocketed by 110700bps in 2020.
  • Over the past 4 years, Ironwood Pharmaceuticals' Gross Margin (Quarter) stood at 90.46% in 2017, then decreased by -8bps to 83.58% in 2018, then rose by 9bps to 91.28% in 2019, then grew by 9bps to 99.23% in 2020.
  • Its Gross Margin was 99.23% in Q4 2020, compared to 100.0% in Q3 2020 and 100.0% in Q2 2020.